SBRA Price Prediction Next Week
Technical Analysis: SBRA is currently trading at $16.39, showing a bearish trend in the short term. The stock has formed a descending triangle pattern with resistance at $16.75 and support at $15.78 based on Fibonacci levels.
- RSI (14) at 46.57 indicates neutral momentum
- MACD at -0.20 suggests bearish momentum
- Stochastic (14,3,3) at 42.91 shows the stock is neither overbought nor oversold
- Price is trading below SMA 5, 10, and 20, indicating short-term weakness
- Bollinger Band analysis shows price near the middle band (16.51) with lower band at 15.64
News Analysis:
- Recent JMP Securities upgrade to Market Outperform with $20 price target
- KeyBanc maintained Hold rating as of February 25, 2025
- Positive industry outlook due to softer inflation data and potential rate cuts benefiting REITs
- Strong demographic tailwinds and limited new supply in healthcare REIT sector
Price Prediction for Next Week: Based on technical indicators and Fibonacci levels:
- Resistance levels: $16.71 (R1), $17.00 (R2)
- Support levels: $15.78 (S1), $15.49 (S2)
- Most likely scenario: Stock will trade between $15.78 - $16.71
Trading Recommendation: SELL
- Current price ($16.39) is showing weakness below key moving averages
- Technical indicators suggest bearish momentum
- Recommended to sell with target at $15.78 (S1)
- Place stop loss at $16.71 (R1)
SBRA Revenue Forecast
SBRA EPS Forecast
SBRA FAQs
What is bull’s view on SBRA?
What is bear's view on SBRA?
What is SBRA revenue forecast for next quarter？
SBRA Analyst's Forecast
Aaron Hecht
JMP Securities
Hold → Buy
2025-01-07
Price Target
$20
Upside
+16.41%
JMP Securities upgraded Sabra Health Care to Outperform from Market Perform with a $20 price target. The firm expects "multiple tailwinds to result in outsized returns" for the stock. Sabra will have a "unique and value-creating year" in 2025 for multiple reasons, including its tenant operating troubles related to the pandemic being functionally over, the analyst tells investors in a research note. Further, JMP says the company's skilled nursing rent coverage ratios should continue to expand given the reporting methodology and a strong Medicaid rate environment. Third, Sabra's senior housing assets are poised for multi-year growth due to a significant shortfall of development, contends the firm.
Nicholas Yulico
Scotiabank
Hold
2024-10-11
Price Target
$17 → $18
Downside
-0.11%
John Kilichowski
Wells Fargo
Hold → Buy
2024-10-01
Price Target
$16 → $20
Upside
+7.64%
